Tryp Therapeuatics (TRYPF) Coverage Report

MANAGEMENT BIOGRAPHIES Key members of the executive board include: Greg McKee, Chairman and Chief Executive Officer. Mr. McKee brings more than 20 years of biotechnology, life sciences management and leadership and venture investment experience to the company. Before joining Tryp, he founded Torrent Ventures, and served as chief executive officer of CONNECT, the largest Southern California start-up accelerator creating and scaling innovative life sciences and technology companies. Prior to CONNECT he was chairman, president, and CEO of publicly traded Nventa Biopharmaceuticals which successfully merged with Akela Pharma. Additionally, he has held senior management roles at Genzyme Corporation, which was acquired by Sanofi for $22 billion. Mr. McKee has lived and worked in Tokyo, Japan for seven years managing a $550M investment portfolio at the Mizuho Group and as an investment banker with UBS. He was also senior advisor to the Former Minister of Foreign Affairs of Japan. Additionally, Mr. McKee lived and worked in Singapore for two years, managing Genzyme's business units in Southeast Asia and mainland China. Mr. McKee earned a B.A. in Economics from the University of Washington, a M.A. in International Studies from The Joseph H. Lauder Institute and an M.B.A from the Wharton School, at the University of Pennsylvania. He has been a member of Young President's Organization (YPO) since 2006. Luke Hayes, Chief Financial Officer. Mr. Hayes has been active in the life science industry for more than 20 years with experience in technology transfer, venture capital, and finance. Mr. Hayes started his career doing business development for Dow Chemical with responsibility for pharmaceutical customers including Lilly and AbbVie. Mr. Hayes spent more than a decade doing venture capital investing while supporting a wide range of companies as a director and advisor. Mr. Hayes has deep experience with corporate finance and capital formation activities as well as extensive relationships throughout the life science industry. James Gilligan, Ph.D., President & Chief Science Officer. Dr. Gilligan has over 35 years of experience in the life sciences industry, including R&D, clinical development, international regulatory affairs, and manufacturing. Prior to joining Tryp Therapeutics, Dr. Gilligan was a Co-Founder and Managing Partner of The Bracken Group, a life sciences consulting firm providing regulatory and product development support to pharmaceutical and biotech companies. Dr. Gilligan was a co-founder of Unigene Laboratories, which develops technology for the recombinant manufacture of peptide hormones, as well as oral and nasal delivery technologies for peptide-based therapeutics. He was also a Co- Founder and the Chief Scientific Officer of Tarsa Therapeutics. Dr. Gilligan received a Ph.D., from University of Connecticut and a master’s in international business from Seton Hall University. He continued his post-graduate education at the Roche Institute of Molecular Biology. Tom D’orazio, Chief Operating Officer. Mr. D’Orazio has extensive experience leading the development and commercialization of vaccines, drugs, radiopharmaceuticals, and biologics. His leadership experience has been in commercial planning, business development, marketing, and partnership management roles. Mr. D’Orazio was formerly the CEO of ImmunoPrecise Antibodies where he led the transition from a private company to a public company. He co-founded and led Superna Life Sciences as CEO, a specialty- pharma company focusing on niche drugs for cancer patients in Canada where he successfully in-licensed two products and succeeded in getting Health Canada approval for both drugs in head & neck cancer and prostate cancer respectively. Mr. D’Orazio has commercialization experience at all stages of drug development primarily in oncology, rare diseases, and ophthalmology products respectively. Mr. D’Orazio held roles in business development doing both in-licensing and out-licensing as well as managing partnerships Michael Higgins 212.409.2074 Tryp Therapeutics, Inc. (TRYPF) Page 35